Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL patients, offering treatment-free intervals. Safety profiles differed, with ...
Pirtobrutinib significantly improved progression-free survival in untreated CLL/SLL patients compared to standard chemoimmunotherapy in the BRUIN CLL-313 trial. Early trends suggest potential overall ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback